Amira Pharmaceuticals Inc.

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, a Back-Up to Amira's Lead DP2 Antagonist, AM211.
Clinical Trials Week; 12/14/2009; 830 words; Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study...antagonist of the DP2 (also known as CRTH2) receptor (see also Amira Pharmaceuticals, Inc.). The interim results demonstrate that a dose proportional...

Clinic Roundup.
BIOWORLD Today; 12/4/2009; 1062 words; o Amira Pharmaceuticals Inc., of San Diego, reported initial data...safety profile. AM461 is a back-up to Amira's lead DP2 antagonist, AM211, which...tolerability. o Cubist Pharmaceuticals Inc., of Lexington, Mass., announced...

Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211.
PR Newswire Europe; 12/3/2009; 876 words; ...cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity...R). The drug hunters at Amira are now actively leveraging...russopartnersllc.com, for Amira Pharmaceuticals, Inc.

Publication No. WO/2009/140642 Published on Nov. 19, Assigned to AMIRA PHARMACEUTICALS for Tricyclic Antagonist (American Inventors)
US Fed News Service, Including US State News; 11/24/2009; 406 words; ...d2 receptors. The patent has been assigned to AMIRA PHARMACEUTICALS INC., San Diego. According to an abstract posted...antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the...

Reportlinker Adds Pulmonary Drug Delivery Technologies - A Global Market Perspective.
PR Newswire; 11/18/2009; 2277 words; ...Perspective" by BizAcumen, Inc. Our reports are designed...GlaxoSmithKline Ties-Up with Amira Pharmaceuticals 19 Consort Medical Releases...Division (USA) 23 Akela Pharma Inc (Canada) 23 Alkermes, Inc. (USA) 23 Aradigm Corporation...